Dianthus Therapeutics (87E) AI Stock Analysis

0 Followers

Dianthus Therapeutics

(XETRA:87E)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverage and capital baseExtremely low leverage limits financial risk from borrowing and preserves flexibility for research, development, and other capital needs. The substantially larger equity base provides Dianthus with a stronger solvency position than many development-stage companies, although it does not yet generate profits.

Negative Factors

No commercial product revenueWithout marketed products, Dianthus lacks a recurring commercial revenue stream to fund operations and validate its business model through customer demand. Financial progress therefore remains dependent on development outcomes and external financing until a therapy can be successfully approved and commercialized.

Dianthus Therapeutics (87E) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 5.03B
Dividend Yield: ―
Average Volume (3M): 69
Price to Earnings (P/E): 3000.0
Beta (1Y): 0.09
Revenue Growth: -17.89%
EPS Growth: -8.86%
Country: Germany
Employees: 92
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Dianthus Therapeutics Business Overview & Revenue Model

Company Description

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended...

Dianthus Therapeutics Risk Analysis

Dianthus Therapeutics disclosed 72 risk factors in its most recent earnings report. Dianthus Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Dianthus Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:87E against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	55Neutral	$3.24B	-7.80	-69.76%	―	-62.83%	-18.22%
VERA	53Neutral	$2.15B	-5.19	-90.03%	―	―	-48.21%
NAMS	52Neutral	$2.27B	-11.11	-31.39%	―	-26.41%	16.12%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMER	48Neutral	$1.22B	9.19	-109.40%	―	―	―
TVTX	48Neutral	$4.76B	-33.10	-186.46%	―	49.38%	-58.47%

* Healthcare Sector Average

Performance Comparison

DE:87E and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:87E	Dianthus Therapeutics, Inc.	76.50	45.50	146.77%
OMER	Omeros Corporation	16.92	10.03	145.57%
TVTX	Travere Therapeutics, Inc.	49.60	13.13	36.00%
VRDN	Viridian Therapeutics, Inc.	28.49	-0.45	-1.55%
NAMS	Newamsterdam Pharma Company N.V.	18.90	-19.41	-50.67%
VERA	Vera Therapeutics, Inc.	29.79	-1.29	-4.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Dianthus Therapeutics AI Stock Analysis